IWR-1-endo

For research use only. Not for use in humans.

目录号:S7086 别名: endo-IWR 1

IWR-1-endo Chemical Structure

CAS No. 1127442-82-3

IWR-1-endo (endo-IWR 1)是一种Wnt通路抑制剂,在表达 Wnt3A 的 L-细胞中IC50为180 nM,诱导Axin2蛋白水平,并通过稳定Axin骨架破坏复合体来促进β-catenin磷酸化。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 975.58 现货
RMB 900.38 现货
RMB 2050.64 现货
RMB 5151.51 现货
有超大折扣
今日订购,明日送达 全国免运费 分装免费
全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的IWR-1-endo发表文献76篇:

产品安全说明书

Wnt/beta-catenin抑制剂选择性比较

生物活性

产品描述 IWR-1-endo (endo-IWR 1)是一种Wnt通路抑制剂,在表达 Wnt3A 的 L-细胞中IC50为180 nM,诱导Axin2蛋白水平,并通过稳定Axin骨架破坏复合体来促进β-catenin磷酸化。
靶点
Wnt [1]
(L-cells expressing Wnt3A)
180 nM
体外研究

IWR-1 和XAV939作为Wnt通路的可逆抑制剂,在体内外具有相似的药理作用,IWR-1通过与Axin相互作用而发挥效果,而XAV939直接与TNKS结合。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BL21 (DE3) MVLGeY5kfGmxbjDhd5NigQ>? MUG5NEBucW6| MWrBZ5Rqfmm2eTDv[kBPNXSncn3pcpV{KGineHHIbZMufGGpZ3XkJIh2dWGwIGTOV2szKGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEhMESHMzmgZ4VtdHNidYPpcoch[mmxdHnufYxifGWmIF7BSEsh[XNic4Xid5Rz[XSnIHHmeIVzKDlyIH3pcpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nzMEBGSzVyIE2gNE4zKM7:TT6= MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ|M{OyNEc,OjJ{M{OzNlA9N2F-
SW480 M165bWZ2dmO2aX;uJIF{e2G7 M2S1UFI1KGi{cx?= NEPwfo5KdmirYnn0bY9vKG:oIIThcot6emG|ZTDpckBpfW2jbjDTW|Q5OCClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yh[XirbkKgZYZ1\XJiMkSgbJJ{KGK7IFjv[YNpe3RiZInlMYJie2WmIH3leIhw\CxiRVO1NEA:KDJwNTFOwG0v NUPaXGJURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NFE2OTdpPkKzO|AyPTF5PD;hQi=>
HEK293T MX\GeY5kfGmxbjDhd5NigQ>? NELDU5ZKdmirYnn0bY9vKG:oIHLleIEu[2G|ZXnuMYRmeGWwZHXueEBk[W6xbnnjZYwhX262MzDwZZRpf2G7IHnuJIh2dWGwIFjFT|I6O1RiY3XscJMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyIE2gNE4xOjZizszNMi=> NHnj[IE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG5NVU2Pyd-MkKxPVE2PTd:L3G+
SW480 M1rrbWZ2dmO2aX;uJIF{e2G7 M1nlUVQxKHSxIES4JIhzew>? NWTuTGtlUW6qaXLpeIlwdiCxZjD0ZY5sgXKjc3WgbY4hcHWvYX6gV3c1QDBiY3XscJMh[XO|ZYPz[YQh[XNiZHXndoFl[XSrb36gc4Yh[mW2YTDjZZRmdmmwIHHmeIVzKDRyIITvJFQ5KGi{czygTWM2OCB;IECuNlUh|ryPLh?= MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdyMUWxO{c,OjN5MEG1NVc9N2F-
L-Wnt-STF NHPIbYpHfW6ldHnvckBie3OjeR?= NVTEO5RiOjRiaILz NVm2WpBnUW6qaXLpeIlwdiCxZjDUUmtUNTJiaX6gcY92e2ViTD3XcpQuW1SIIHPlcIx{KGG|c3Xzd4VlKGG|IHTpd5J2eHSrb36gc4YhX262IIPp[45idGmwZzDh[pRmeiB{NDDodpMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyIE2gNE4xPTZizszNMi=> NV7KfpZpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1Nlc4QTJpPkK0OVI4Pzl{PD;hQi=>
L-Wnt-STF NEi2V2NHfW6ldHnvckBie3OjeR?= M324flI1KGi{cx?= NUG3OlYzUW6qaXLpeIlwdiCxZjDUUmtUNTFiaX6gcY92e2ViTD3XcpQuW1SIIHPlcIx{KGG|c3Xzd4VlKGG|IHTpd5J2eHSrb36gc4YhX262IIPp[45idGmwZzDh[pRmeiB{NDDodpMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyIE2gNE4yOzFizszNMi=> NIfWepo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyO|c6Oid-MkS1Nlc4QTJ:L3G+
HT29 M2n6NWZ2dmO2aX;uJIF{e2G7 Ml70NlQhcHK| MVLJcohq[mm2aX;uJI9nKFewdDDzbYdv[WyrbnegbY4hcHWvYX6gTHQzQSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIJmfGFvY3H0[Y5qdi2vZXTpZZRm\CCWY3[vUIVnKHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fUBi\nSncjCyOEBpenNiYomg[JVidCCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmgdoVt[XSrdnWgeI8h[2:wdILvcEwhUUN3MDC9JFI1NjRizszNMi=> M4DzUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUWwOFg6Lz5{NEm1NFQ5QTxxYU6=
DLD1 NGjSN2FHfW6ldHnvckBie3OjeR?= MoLGNVAhfU1? Ml;rTY5lfWO2aX;uJI9nKEG6aX6yJIlvKGi3bXHuJGRNTDFiY3XscJMhd3[ncnX4dJJme3OrbnegTXdTNUmVIHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKFewdDDwZZRpf2G7IHHjeIl3cXS7IHH0JFExKHWPIHL5JHNVTiC{ZYDvdpRmeiCjc4PhfUBu\XSqb3S= M33UTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUK1NVU3Lz5zOUGyOVE2PjxxYU6=
HEK293 M2j6dGZ2dmO2aX;uJIF{e2G7 NIHyTXpFcXOybHHj[Y1mdnRib3[gTXdTNVCEIH\yc40hSXirbkKgbY4hUEWNMkmzJINmdGy|IHL5JHdme3Sncn6gZoxwfCCvZYToc4Q> MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF{NUG1Okc,OTlzMkWxOVY9N2F-
DLD1 M4\meWZ2dmO2aX;uJIF{e2G7 NHTjdWdKdmirYnn0bY9vKG:oIFH4bY4zKHC{b4TlbY4h\GWpcnHkZZRqd25iaX6gbJVu[W5iRFzENUBk\WyuczDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF{NUG1Okc,OTlzMkWxOVY9N2F-
DLD1 NFLMToFHfW6ldHnvckBie3OjeR?= Ml:wTY5lfWO2aX;uJI9nKEG6aX6yJIFk[3WvdXzheIlwdiCrbjDoeY1idiCGTFSxJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKFSqckSxJJBpd3OyaH;yfYxifGWmIHLleIEu[2G|ZXnuJIxmfmWuczDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? NH;XXpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGyOVE2Pid-MUmxNlUyPTZ:L3G+
DLD1 NHLIZ2dHfW6ldHnvckBie3OjeR?= NHH2fW1KdmS3Y4Tpc44hd2ZiQYjpclIh[WOldX31cIF1cW:wIHnuJIh2dWGwIFTMSFEh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iU3XyN|cheGixc4Doc5J6dGG2ZXSgZoV1[S2lYYPlbY4hdGW4ZXzzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= NVLzZnplRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNlUyPTZpPkG5NVI2OTV4PD;hQi=>
DLD1 M4LSdGZ2dmO2aX;uJIF{e2G7 NXiyTHplTGWlcnXhd4UhcW5iYnX0ZU1k[XOnaX6gZYNkfW23bHH0bY9vKGmwIHj1cYFvKESOREGgZ4VtdHNiZYjwdoV{e2mwZzDpckBCWENibYX0ZY51 M172fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUK1NVU3Lz5zOUGyOVE2PjxxYU6=
DLD1 NH3LWYVHfW6ldHnvckBie3OjeR?= NFPOeXkzKGi{cx?= NUDhUnQ1UW6mdXP0bY9vKG:oIFH4bY4zKHO2YXLpcIl7[XSrb36gbY4hcHWvYX6gSGxFOSClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\WRidILhcpNkemmydHnvckBw\iCDeHnuNkBi\nSncjCyJIhzeyCkeTDSWE1RS1JibXX0bI9l M3TT[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUK1NVU3Lz5zOUGyOVE2PjxxYU6=
DLD1 MVHGeY5kfGmxbjDhd5NigQ>? NHTCSo1KdmS3Y4Tpc44hd2ZiQYjpclIh[WOldX31cIF1cW:wIHnuJIh2dWGwIFTMSFEh[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iZoLl[UBj\XSjLXPhd4VqdiCuZY\lcJMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz NVLTRZpwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNlUyPTZpPkG5NVI2OTV4PD;hQi=>
DLD1 NH;qTGVHfW6ldHnvckBie3OjeR?= NG\aUXBKdmS3Y4Tpc44hd2ZiQYjpclIhe3SjYnnsbZpifGmxbjDpckBpfW2jbjDEUGQyKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gW451N2KndHGtZ4F{\WmwIIDheIh4[Xl? NHrsRos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGyOVE2Pid-MUmxNlUyPTZ:L3G+
DLD1 M4TB[mZ2dmO2aX;uJIF{e2G7 NY\4eGh7UW6mdXP0bY9vKG:oIFH4bY4zKGGlY4XteYxifGmxbjDpckBpfW2jbjDEUGQyKGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIGPldlM{KHCqb4PwbI9zgWyjdHXkJIJmfGFvY3Hz[YlvKGyndnXsd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= NHvHWmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGyOVE2Pid-MUmxNlUyPTZ:L3G+
DLD1 NWPuTGhzTnWwY4Tpc44h[XO|YYm= NEf6e2ZKdmS3Y4Tpc44hd2ZiQYjpclIh[WOldX31cIF1cW:wIHnuJIh2dWGwIFTMSFEh[2WubIOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| M1PWTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUK1NVU3Lz5zOUGyOVE2PjxxYU6=
DLD1 NIfKbHhHfW6ldHnvckBie3OjeR?= MV2xJJRwKDJyIIXN NWXpfXgzOjRiaILz M2fiPWlvcGmkaYTpc44hd2ZidHHub5lz[XOnIHnuJIh2dWGwIFTMSFEh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDUR2Yu\GWyZX7k[Y51KHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fUBifCBzIITvJFIxKHWPIHHmeIVzKDJ2IHjyd{BjgSCmdXHsJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>? MnzlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3Mke3PVIoRjJ2NUK3O|kzRC:jPh?=
DLD1 MlzQR5l1d3SxeHnjbZR6KGG|c3H5 M1;LSFEhfG9iMkCgeW0> M1rQ[VExKGSjeYO= NXr2T|RJS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTEyGMTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDheEAyKHSxIEKwJJVOKG2nYYP1doVlKG:wIHThfUAyOCCkeTDjdpl{fGGuII\pc4xmfCC|dHHpcolv\w>? MmnDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3Mke3PVIoRjJ2NUK3O|kzRC:jPh?=
HT29 NXzae4p1TnWwY4Tpc44h[XO|YYm= NX3YSXhbOjVidV2= NV3PRnd6OjRiaILz NF;lUFdKdmirYnn0bY9vKG:oIGfueEB{cWewYXzpcochcW5iaIXtZY4hUFR{OTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGKndHGtZ4F1\W6rbj3t[YRq[XSnZDDUZ4YwVGWoIITyZY5{[3KrcITpc45idCCjY4Tpeol1gSCjdDCyOUB2VSCjZoTldkAzPCCqcoOgZpkh\HWjbDDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZkhemWuYYTpeoUhfG9iY3;ueJJwdA>? NYjBbWI2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OVA1QDlpPkK0PVUxPDh7PD;hQi=>
HT29 MmXLSpVv[3Srb36gZZN{[Xl? NGfPT|AzPSC3TR?= Mkf1NlQhcHK| MkXMTY5pcWKrdHnvckBw\iCZboSgd4lodmGuaX7nJIlvKGi3bXHuJGhVOjliY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBj\XSjLXPheIVvcW5vbXXkbYF1\WRiVHPmM2xm\iC2cnHud4NzcXC2aX;uZYwh[WO2aY\peJkh[XRiMkWgeW0h[W[2ZYKgNlQhcHK|IHL5JIR2[WxibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5JJJmdGG2aY\lJJRwKGOxboTyc4whcW5icILld4Vv[2Vib3[gS3NMNTOkZYThJIlvcGmkaYTvdkBNcUOu NUf3WnJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OVA1QDlpPkK0PVUxPDh7PD;hQi=>
HT29 NEjSfnpHfW6ldHnvckBie3OjeR?= NXPoVZRjOjVidV2= M1voSlI1KGi{cx?= M2\6T2lvcGmkaYTpc44hd2ZiV370M4JmfGFvY3H0[Y5qdiC|aXfuZYxqdmdiaX6gbJVu[W5iSGSyPUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjeHnuNkBuWk6DIHX4dJJme3Orb36gZZQhOjVidV2gZYZ1\XJiMkSgbJJ{KGK7IIH1ZY51cXSjdHn2[UBz\WGuLYTpcYUhWEOUIHHzd4F6 NEjHOGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1NFQ5QSd-MkS5OVA1QDl:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
E-cadherin / N-cadherin / Snail / Vimentin; 

PubMed: 26450645     


Western blot analyses showing protein expression patterns of the EMT markers according to IWR-1 dose and exposure time. β-Actin was used as a loading control.

p-Akt / Akt; 

PubMed: 26450645     


Western blot analysis showing that IWR-1 decreased the phosphorylation of Akt in a concentration- and time-dependent manner, respectively.

Survivin; 

PubMed: 26450645     


Western blot analysis showing that IWR-1 decreased the survivin expression in a concentration- and time-dependent manner, respectively.

26450645

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 21 mg/mL (51.28 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 409.44
化学式

C25H19N3O3

CAS号 1127442-82-3
储存条件 粉状
溶于溶剂
别名 endo-IWR 1

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Wnt/beta-catenin Signaling Pathway Map

相关Wnt/beta-catenin产品

Tags: 购买IWR-1-endo | IWR-1-endo供应商 | 采购IWR-1-endo | IWR-1-endo价格 | IWR-1-endo生产 | 订购IWR-1-endo | IWR-1-endo代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID